Francisco Gimenez is Partner at 8VC and focuses on Bio-IT investments. He received his Ph.D. from Stanford in Biomedical Informatics and B.S. in Electrical Engineering and Computer Sciences from UC Berkeley. In this episode, Francisco explains how breakthroughs in AI, gene editing, and cell therapies converged to jumpstart a new age in biology. He predicts that biomanufacturing platforms, armed with mountains of data and new tools, will bring down the costs of creating and commercializing drugs so smaller companies can treat rarer diseases and deliver more personalized cures. By decentralizing the pharma industry, Francisco is optimistic that the future of medicine will evolve from reactive care to preventative medicine that will help people fully self-actualize and lead their best, healthiest lives. [Joe is a founding partner of 8VC, his venture capital firm.] This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit blog.joelonsdale.com

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related